SINOVAC Secures Exclusive 2026 Influenza Vaccine Supply Contract in Chile

BEIJING, Jan. 4, 2026 — SINOVAC Biotech Ltd. ("SINOVAC" or the "Company"), a leading global provider of biopharmaceutical products, has been awarded an exclusive contract under the Chilean government's 2026 global tender for seasonal influenza vaccines, with an order exceeding 8 million doses. The first batch of vaccines is scheduled to be delivered to Chile by the end of January 2026, ahead of the country's upcoming influenza season.

This award marks the second consecutive year SINOVAC has served as the sole provider for Chile's national influenza immunization efforts. The selection follows the successful execution of the 2025 program, during which SINOVAC-supplied vaccines supported the administration of 8.3 million doses, facilitating an approximately 80% vaccination rate among the nation's target populations.

SINOVAC's engagement in Chile extends beyond product supply to include multi-year clinical research collaborations. In August 2024, results from an international, multicenter clinical study of SINOVAC's quadrivalent influenza vaccine were published in the peer-reviewed journal Vaccines, demonstrating immunogenicity and safety outcomes, with antibody responses against all four influenza strains exceeding those of comparator vaccines. More recently, a Phase III study conducted in adult populations in Chile, evaluating both humoral and cellular immune responses, was published in Nature Communications, further supporting the scientific basis of the vaccine's immunogenicity and safety.

To date, SINOVAC's influenza vaccines have been authorized in nearly 20 countries and regions. With cumulative global deliveries exceeding 120 million doses, the Company continues to strengthen its role in global respiratory disease prevention through consistent manufacturing quality and a robust evidence-based clinical program.

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of "supply vaccines to eliminate human diseases", the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases.

The company's diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, etc., of which 3 vaccines have been prequalified by WHO, including inactivated hepatitis A vaccine Healive®, Sabin-strain inactivated polio vaccine (sIPV), and varicella vaccine.

SINOVAC has a leading edge in developing vaccines to combat infectious disease outbreaks and was among the first to initiate R&D during major public health emergencies, including SARS, H5N1, H1N1, and COVID-19. The company developed the world's first inactivated SARS vaccine (Phase I completed), China's first H5N1 influenza vaccine (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the most widely used inactivated COVID-19 vaccine globally.

Beyond its marketed portfolio, the company is advancing a robust pipeline that includes combination vaccines,recombinant protein vaccines and next-generation platforms such as mRNA technologies and antibodies.

With a long-standing commitment to innovation and global health, SINOVAC is expanding its global footprint by strengthening partnerships with research institutions, international organizations, and local partners. Through broader market presence, technological cooperation, and localized production, the company aims to accelerate vaccine development and supply, enhance regional access to high-quality products, and better address unmet medical needs while improving preparedness for future pandemics.

For more information, please see the Company’s website at www.sinovac.com.